An Indian Post Marketing Study of Mealtime Insulin, Fiasp®, to Evaluate Its Safety and Effectiveness in Patients With Diabetes Mellitus in Routine Clinical Practice

NCT03987802 · clinicaltrials.gov ↗

COMPLETED

Status

42

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 1
Diabetes Mellitus, Type 2

Interventions

DRUG: Faster-acting insulin aspart

Sponsor

Novo Nordisk A/S